Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.64 |
| ▸ | CTSB | P07858 | 2/20 | 0.64 |
| ▸ | CTSK | P43235 | 2/20 | 0.64 |
| ▸ | USP7 | Q93009 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.39 |
| ▸ | TEAD4 | Q15561 | 3/20 | 0.39 |
| ▸ | TEAD2 | Q15562 | 3/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22061852 | 0.81 | CTSL (0.52) | CTSLCTSBCTSKUSP7MEN1 | |
| SCHEMBL6859782 | 0.79 | CTSL (1.00) | CTSLCTSBCTSKUSP7MEN1 | |
| SCHEMBL9705360 | 0.76 | CTSL (0.47) | CTSLCTSBCTSKUSP7KMT2A | |
| SCHEMBL6858871 | 0.75 | CTSL (0.47) | CTSLCTSBCTSKUSP7TEAD1 | |
| SCHEMBL4642766 | 0.70 | HTR3A (0.48) | MEN1KMT2AOPRM1 | |
| SCHEMBL29854087 | 0.70 | HTR3A (0.48) | MEN1KMT2AOPRM1 | |
| SCHEMBL2327219 | 0.68 | MAOA (0.52) | CTSLCTSBCTSKUSP7MEN1 | |
| SCHEMBL30043742 | 0.68 | MAOA (0.52) | CTSLCTSBCTSKUSP7MEN1 | |
| SCHEMBL819997 | 0.65 | CA1 (0.52) | CA1CA2 | |
| SCHEMBL1808685 | 0.65 | MEN1 (0.52) | MEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | claimed |
| US-6835727-B2 | Bone disorders; osteoporosis; rheumatic diseases | MERCK FROSST CANADA & CO. (CA) | 2004-12-28 | — | — | US | disclosed |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | CTSK, CTSZ, CTSE | CTSL 10/4885CTSB 5/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.